The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia

Current Pharmaceutical Design

Volumn 20, Issue 31, 2014, Pages 5069-5076

  Gill, Kathryn M ^a   Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Dopamine; Hippocampus; Positive allosteric modulator; Receptors; Schizophrenia; Ventral tegmental area

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5 STIMULATING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; DOPAMINE; PARVALBUMIN; UNCLASSIFIED DRUG; NOOTROPIC AGENT;

4 AMINOBUTYRIC ACID RELEASE; ALLOSTERISM; ARTICLE; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; GAMMA RHYTHM; HIPPOCAMPUS; HUMAN; INTERNEURON; MEMORY DISORDER; NEGATIVE SYNDROME; NERVE CELL NETWORK; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOPHARMACOTHERAPY; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; VENTRAL TEGMENTUM; WORKING MEMORY; COGNITIVE THERAPY; NEUROMODULATION; OSCILLATION; ANIMAL; BIOLOGICAL MODEL; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; COGNITION DISORDERS; DOPAMINE; GABA-A RECEPTOR AGONISTS; HIPPOCAMPUS; HUMANS; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; NOOTROPIC AGENTS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84906226176     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131216114612     Document Type: Article

References (119)

1. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CA- TIE and other trials. J Clin Psychiatry 2007; 68: e04.
2. Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008; 59: 523-525.
3. Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol 2012: 53-86.
4. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
5. Wang XJ, Buzsaki G. Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model. J Neurosci 1996; 16: 6402-6413.
6. Penttonen M, Kamondi A, Acsady L, Buzsaki G. Gamma frequency oscillation in the hippocampus of the rat: intracellular analysis in vivo. Eur J Neurosci 1998; 10: 718-728.
7. Buhl EH, Tamas G, Fisahn A. Cholinergic activation and tonic excitation induce persistent gamma oscillations in mouse somato-sensory cortex in vitro. J Physiol 1998; 513 (Pt 1): 117-126.
8. Chrobak JJ, Buzsaki G. Gamma oscillations in the entorhinal cortex of the freely behaving rat. J Neurosci 1998; 18: 388-398.
9. Bragin A, Jando G, Nadasdy Z, Hetke J, Wise K, Buzsaki G. Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat. J Neurosci 1995; 15: 47-60.
10. Lisman JE, Idiart MA. Storage of 7 +/- 2 short-term memories in oscillatory subcycles. Science 1995; 267: 1512-1515.
11. Fisahn A, Pike FG, Buhl EH, Paulsen O. Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro. Nature 1998; 394: 186-189.
12. Buzsáki G. Rhythms of the brain. Oxford University Press: Oxford; New York 2006.
13. Magri C, Schridde U, Murayama Y, Panzeri S, Logothetis NK. The amplitude and timing of the BOLD signal reflects the relationship between local field potential power at different frequencies. J Neu-rosci 2012; 32: 1395-1407.
14. Gruber AJ, Hussain RJ, O'Donnell P. The nucleus accumbens: a switchboard for goal-directed behaviors. PLoS One 2009; 4: e5062.
15. McCracken CB, Grace AA. High-frequency deep brain stimulation of the nucleus accumbens region suppresses neuronal activity and selectively modulates afferent drive in rat orbitofrontal cortex in vivo. J Neurosci 2007; 27: 12601-12610.
16. Ewing SG, Grace AA. Long-term high frequency deep brain stimulation of the nucleus accumbens drives time-dependent changes in functional connectivity in the rodent limbic system. Brain Stimul 2013; 6: 274-285.
17. Lapish CC, Chiang J, Wang JZ, Phillips AG. Oscillatory power and synchrony in the rat forebrain are altered by a sensitizing regime of D-amphetamine. Neuroscience 2012; 203: 108-121.
18. Stahl D, Ferger B, Kuschinsky K. Sensitization to d-amphetamine after its repeated administration: evidence in EEG and behaviour. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 335-340.
19. Rehme AK, Grefkes C. Cerebral network disorders after stroke: evidence from imaging-based connectivity analyses of active and resting brain states in humans. J Physiol 2013; 591: 17-31.
20. Brazhnik E, Cruz AV, Avila I, et al. State-dependent spike and local field synchronization between motor cortex and substantia ni-gra in hemiparkinsonian rats. J Neurosci 2012; 32: 7869-7880.
21. Buzsaki G. Hippocampal GABAergic interneurons: a physiological perspective. Neurochem Res 2001; 26: 899-905.
22. Volman V, Behrens MM, Sejnowski TJ. Downregulation of par-valbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci 2011; 31: 18137-18148.
23. Buzsaki G. Functions for interneuronal nets in the hippocampus. Can J Physiol Pharmacol 1997; 75: 508-515.
24. Korotkova T, Fuchs EC, Ponomarenko A, von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbumin-positive in-terneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 2010; 68: 557-569.
25. Vreugdenhil M, Jefferys JG, Celio MR, Schwaller B. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. J Neurophysiol 2003; 89: 1414-1422.
26. Curley AA, Eggan SM, Lazarus MS, Huang ZJ, Volk DW, Lewis DA. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. Neurobiol Dis 2013; 50: 179-186.
27. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorso-lateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010; 167: 1479-1488.
28. Sakai T, Oshima A, Nozaki Y, et al. Changes in density of cal-cium-binding-protein-immunoreactive GABAergic neurons in pre-frontal cortex in schizophrenia and bipolar disorder. Neuropathol-ogy 2008; 28: 143-150.
29. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315-6326.
30. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52: 708-715.
31. Zhang Z, Sun J, Reynolds GP. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin Med J (Engl) 2002; 115: 819-823.
32. Kalus P, Bondzio J, Federspiel A, Muller TJ, Zuschratter W. Cell-type specific alterations of cortical interneurons in schizophrenic patients. Neuroreport 2002; 13: 713-717.
33. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefron-tal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am J Psychiatry 2001; 158: 1411-1422.
34. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A 2007; 104: 10164-10169.
35. Morris HM, Hashimoto T, Lewis DA. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008; 18: 1575-1587.
36. Konradi C, Yang CK, Zimmerman EI, et al. Hippocampal interneu-rons are abnormal in schizophrenia. Schizophr Res 2011; 131: 165-173.
37. Cardin JA, Carlen M, Meletis K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 2009; 459: 663-667.
38. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009; 459: 698-702.
39. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci 2009; 29: 2344-2354.
40. Francois J, Ferrandon A, Koning E, Angst MJ, Sandner G, Nehlig A. Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol 2009; 12: 1097-1110.
41. Howard MW, Rizzuto DS, Caplan JB, et al. Gamma oscillations correlate with working memory load in humans. Cereb Cortex 2003; 13: 1369-1374.
42. Barr MS, Farzan F, Tran LC, Chen R, Fitzgerald PB, Daskalakis ZJ. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophr Res 2010; 121: 146-152.
43. Basar-Eroglu C, Brand A, Hildebrandt H, Karolina Kedzior K, Mathes B, Schmiedt C. Working memory related gamma oscillations in schizophrenia patients. Int J Psychophysiol 2007; 64: 39-45.
44. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A 2006; 103: 19878-19883.
45. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
46. Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin? Curr Opin Neurol 2012; 25: 708-714.
47. Kahn RS, Keefe RS. Schizophrenia Is a Cognitive Illness: Time for a Change in Focus. JAMA Psychiatry 2013.
48. Crespo-Facorro B, Roiz-Santianez R, Perez-Iglesias R, et al. Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychol Med 2011; 41: 1449-1460.
49. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157: 549-559.
50. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315-336.
51. Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001; 22: 188-194.
52. Wafford KA, Macaulay AJ, Fradley R, O'Meara GF, Reynolds DS, Rosahl TW. Differentiating the role of gamma-aminobutyric acid type A (GABAA) receptor subtypes. Biochem Soc Trans 2004; 32: 553-556.
53. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000; 101: 815-850.
54. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996; 19: 139-143.
55. Quirk K, Blurton P, Fletcher S, et al. [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacology 1996; 35: 1331-1335.
56. Lingford-Hughes A, Hume SP, Feeney A, et al. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab 2002; 22: 878-889.
57. Sur C, Fresu L, Howell O, McKernan RM, Atack JR. Autoradio-graphic localization of alpha5 subunit-containing GABAA receptors in rat brain. Brain Res 1999; 822: 265-270.
58. Serwanski DR, Miralles CP, Christie SB, Mehta AK, Li X, De Blas AL. Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain. J Comp Neurol 2006; 499: 458-470.
59. Christie SB, De Blas AL. Alpha5 Subunit-containing GABA(A) receptors form clusters at GABAergic synapses in hippocampal cultures. Neuroreport 2002; 13: 2355-2358.
60. Beneyto M, Abbott A, Hashimoto T, Lewis DA. Lamina-Specific Alterations in Cortical GABAA Receptor Subunit Expression in Schizophrenia. Cereb Cortex 2010.
61. Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon Weickert C. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res 2010; 44: 673-681.
62. Asai Y, Takano A, Ito H, et al. GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schi-zophr Res 2008; 99: 333-340.
63. Chard PS, Bleakman D, Christakos S, Fullmer CS, Miller RJ. Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 1993; 472: 341-357.
64. Heizmann CW, Hunziker W. Intracellular calcium-binding proteins: more sites than insights. Trends Biochem Sci 1991; 16: 98-103.
65. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci 1992; 15: 303-308.
66. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci 1993; 13: 4908-4923.
67. Gonzalez-Burgos G, Krimer LS, Povysheva NV, Barrionuevo G, Lewis DA. Functional properties of fast spiking interneurons and their synaptic connections with pyramidal cells in primate dorso-lateral prefrontal cortex. J Neurophysiol 2005; 93: 942-953.
68. Whittington MA, Traub RD, Jefferys JG. Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature 1995; 373: 612-615.
69. Cunningham MO, Whittington MA, Bibbig A, et al. A role for fast rhythmic bursting neurons in cortical gamma oscillations in vitro. Proc Natl Acad Sci U S A 2004; 101: 7152-7157.
70. Cunningham MO, Davies CH, Buhl EH, Kopell N, Whittington MA. Gamma oscillations induced by kainate receptor activation in the entorhinal cortex in vitro. J Neurosci 2003; 23: 9761-9769.
71. Pearce RA. Physiological evidence for two distinct GABAA responses in rat hippocampus. Neuron 1993; 10: 189-200.
72. Banks MI, Li TB, Pearce RA. The synaptic basis of GABAA,slow. J Neurosci 1998; 18: 1305-1317.
73. Freund TF, Buzsaki G. Interneurons of the hippocampus. Hippocampus 1996; 6: 347-470.
74. Banks MI, White JA, Pearce RA. Interactions between distinct GABA(A) circuits in hippocampus. Neuron 2000; 25: 449-457.
75. Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci 2008; 28: 1421-1426.
76. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci 2004; 27: 262-269.
77. Caraiscos VB, Elliott EM, You-Ten KE, et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A 2004; 101: 3662-3667.
78. Bonin RP, Martin LJ, MacDonald JF, Orser BA. Alpha5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J Neurophysiol 2007; 98: 2244-2254.
79. Towers SK, Gloveli T, Traub RD, et al. Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol 2004; 559: 721-728.
80. Glykys J, Mody I. Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice. J Neurophysiol 2006; 95: 2796-2807.
81. Spencer KM. Baseline gamma power during auditory steady-state stimulation in schizophrenia. Front Hum Neurosci 2011; 5: 190.
82. Flynn G, Alexander D, Harris A, et al. Increased absolute magnitude of gamma synchrony in first-episode psychosis. Schizophr Res 2008; 105: 262-271.
83. Kikuchi M, Hashimoto T, Nagasawa T, et al. Frontal areas contribute to reduced global coordination of resting-state gamma activities in drug-naive patients with schizophrenia. Schizophr Res 2011; 130: 187-194.
84. Bandyopadhyaya D, Nizamie SH, Pradhan N, Bandyopadhyaya A. Spontaneous gamma coherence as a possible trait marker of schizophrenia-An explorative study. Asian J Psychiatr 2011; 4: 172-177.
85. Hong LE, Summerfelt A, Buchanan RW, et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2010; 35: 632-640.
86. Caixeta FV, Cornelio AM, Scheffer-Teixeira R, Ribeiro S, Tort AB. Ketamine alters oscillatory coupling in the hippocampus. Sci Rep 2013; 3: 2348.
87. Pinault D. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry 2008; 63: 730-735.
88. Symond MP, Harris AW, Gordon E, Williams LM. Gamma synchrony in first-episode schizophrenia: a disorder of temporal connectivity? Am J Psychiatry 2005; 162: 459-465.
89. Williams LM, Whitford TJ, Nagy M, et al. Emotion-elicited gamma synchrony in patients with first-episode schizophrenia: a neural correlate of social cognition outcomes. J Psychiatry Neuro-sci 2009; 34: 303-313.
90. Koenig T, van Swam C, Dierks T, Hubl D. Is gamma band EEG synchronization reduced during auditory driving in schizophrenia patients with auditory verbal hallucinations? Schizophr Res 2012; 141: 266-270.
91. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci 2003; 23: 7407-7411.
92. Bucci P, Mucci A, Merlotti E, Volpe U, Galderisi S. Induced gamma activity and event-related coherence in schizophrenia. Clin EEG Neurosci 2007; 38: 96-104.
93. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neu-rophysiological investigation of the basis of the fMRI signal. Nature 2001; 412: 150-157.
94. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 2002; 22: 5572-5580.
95. Crestani F, Keist R, Fritschy JM, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A 2002; 99: 8980-8985.
96. Prut L, Prenosil G, Willadt S, Vogt K, Fritschy JM, Crestani F. A reduction in hippocampal GABAA receptor alpha5 subunits disrupts the memory for location of objects in mice. Genes Brain Be-hav 2010; 9: 478-488.
97. Martin LJ, Zurek AA, MacDonald JF, Roder JC, Jackson MF, Orser BA. Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J Neurosci 2010; 30: 5269-5282.
98. Hauser J, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hip-pocampal alpha5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol Psychiatry 2005; 10: 201-207.
99. Gerdjikov TV, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. Neuro-biol Learn Mem 2008; 89: 87-94.
100. Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacol-ogy 2007; 53: 810-820.
101. Ballard TM, Knoflach F, Prinssen E, et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 2009; 202: 207-223.
102. Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 2009; 204: 306-312.
103. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-Titus AT, Didriksen M. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopa-mine release in nucleus accumbens. Neuropsychopharmacology 2004; 29: 2052-2064.
104. Gourevitch R, Rocher C, Le Pen G, Krebs MO, Jay TM. Working memory deficits in adult rats after prenatal disruption of neuro-genesis. Behav Pharmacol 2004; 15: 287-292.
105. Featherstone RE, Burton CL, Coppa-Hopman R, Rizos Z, Sinyard J, Kapur S, Fletcher PJ. Gestational treatment with methyla-zoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacol Bio-chem Behav 2009; 93: 382-390.
106. Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ. Ges-tational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharma-cology 2007; 32: 483-492.
107. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neu-robehavioral systems analysis of adult rats exposed to methyla-zoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 2006; 60: 253-264.
108. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 2007; 27: 11424-11430.
109. Schobel SA, Kelly MA, Corcoran CM, et al. Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia. Schizophr Res 2009; 114: 110-118.
110. Schobel SA, Lewandowski NM, Corcoran CM, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009; 66: 938-946.
111. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013; 78: 81-93.
112. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011; 16: 885-886.
113. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
114. Cook JM, Zhou H, Huang S, Sarma PV, Zhang C. Strereospecific and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. In: eds.: United States of America 2009.
115. Fischer BD, Licata SC, Edwankar RV, et al. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Neuropharmacology 2010.
116. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel al-pha5GABA(A)R-positive allosteric modulator reverses hyperacti-vation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 2011; 36: 1903-1911.
117. Costa E, Davis J, Pesold C, Tueting P, Guidotti A. The heterozy-gote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2002; 2: 56-62.
118. Auta J, Impagnatiello F, Kadriu B, Guidotti A, Costa E. Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology 2008; 55: 148-153.
119. Paxinos G, Watson C eds. The rat brain in stereotaxic coordinates. Academic: San Diego 1996.